What Is Cannabidivarin (CBDV)?

Sep 23, 2024

Cannabidivarin, also known as CBDV, is a rare non-intoxicating cannabinoid first isolated in 1969. CBDV may share a similar name to its well-known cousin, cannabidiol, or CBD, but unlike CBD, CBDV is a minor cannabinoid and has demonstrated unique physiological effects. CBDV is one of the many non-psychotropic cannabinoids found in Cannabis sativa plants.

CBDV has a similar molecular structure to CBD but with two fewer carbon atoms on its sidechain. While it can be extracted, this specific rare cannabinoid presents many difficulties separating it from the other cannabinoids. CBDV is one of the most studied rare cannabinoids and has been researched for a myriad of conditions and physiological effects.

CBDV is a Rare Cannabinoid

Unlike well-known cannabinoids tetrahydrocannabinol (THC) and cannabidiol (CBD), which are abundant in the cannabis plant, CBDV is known as a minor cannabinoid and is found in minuscule quantities, making it difficult and cost-prohibitive to extract directly from the plant at a commercial scale.

Therapeutic Potential of CBDV

CBDV has shown potential for treating seizures with fewer side effects compared to current approved anti-epileptic drugs while also noting that further studies are necessary to understand its full clinical implications¹. Rare cannabinoids are an emerging class of compounds that are gaining interest for their potential therapeutic benefits. CBDV exhibits relatively rapid absorption, reaching peak plasma concentrations within about 2 hours after oral administration in animal studies².

Advances in CBDV Production

Modern technologies in cannabinoid manufacturing, such as biosynthesis and chemical synthesis, both used by BayMedica, have enabled the production of rare cannabinoids like CBDV in commercial quantities, making them cost-effective as raw ingredients for various applications.

CBDV’s Complex Interactions in the ECS

The ECS, or Endocannabinoid System, is a complex cell-signaling system that regulates various physiological processes, including mood, pain, immune response, and homeostasis.

Scientific literature suggests CBDV plays a multifaceted role within the Endocannabinoid System (ECS), a critical regulatory network in the body. CBDV is an agonist of transient receptor potential channels, specifically TRPA1, TRPV1, and TRPV2 receptors, which are involved in pain perception and inflammation processes. It also functions as an inverse agonist of GPR6 and an antagonist of GPR55, receptors that influence neurological pathways and immune responses within the ECS.

Furthermore, CBDV may inhibit the production of the endocannabinoid 2-AG, a key signaling molecule in the ECS, by targeting the primary enzyme responsible for its synthesis. While CBDV shows a low affinity for CB1 receptors, which are heavily associated with psychoactive effects, there is an ongoing debate about its binding affinity for CB2 receptors, which play a significant role in immune function and inflammation regulation within the ECS³.

Exploring CBDV’s Therapeutic Applications

Although research into minor cannabinoids is only emerging in the last few years, CBDV has garnered significant attention as one of the most studied rare cannabinoids. Its unique properties have led researchers to investigate its potential across various conditions, particularly its demonstrated anticonvulsant activity. This has made CBDV a subject of interest in both preclinical and clinical studies, where its effects have been explored in various animal and human models to assess its efficacy in treating conditions like epilepsy.

Beyond its potential in epilepsy research, CBDV has also been the focus of studies exploring its impact on other neurological conditions, such as autism spectrum disorder. As the body of research continues to grow, CBDV remains a key compound of interest in the ongoing quest to understand the full spectrum of cannabinoids and their potential therapeutic applications.

Clinical Trials and Pharmacokinetics of CBDV

Currently, there is no regulatory approval of CBDV for therapeutic use for any condition. CBDV has been the subject of clinical trials in several conditions, found on the clinical trials website. Studies have measured the brain elimination half-life of CBDV in mice, highlighting its significance in understanding the cannabinoid’s effects and absorption in neurological applications⁴. Additionally, the plasma elimination half-life of orally administered CBDV is reported to be 222 minutes in mice, which is essential for understanding its potential clinical effects and dosage requirements⁵.

Discover the Potential of CBDV

CBDV is one of several rare cannabinoids meticulously crafted by BayMedica, known for our commitment to quality and innovation. Our CBDV is produced to a purity level exceeding 95% through a process that ensures consistency and efficacy. Each batch is manufactured in compliance with food-grade GMP standards, guaranteeing safety and reliability. To further ensure quality, our cannabinoids undergo rigorous testing at certified laboratories so you can trust the integrity of every product and batch.

As the demand for high-purity rare cannabinoids grows, partnering with a reliable supplier is more important than ever. Whether you’re looking to enhance your product offerings or explore new formulations, our CBDV offers unparalleled potential in various applications.

Contact one of our approved CBDV distribution partners today to learn how to incorporate this exceptional cannabinoid into your next product.

View Our CBDV Distributors

Sources: